Trial record 12 of 31 for:    Open Studies | "Dizziness"

Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2006 by University Hospital Muenster.
Recruitment status was  Recruiting
Information provided by:
University Hospital Muenster Identifier:
First received: August 18, 2005
Last updated: April 11, 2006
Last verified: April 2006

Angiographies of the supra-aortic vessels by magnetic imaging have become common recently. So it was the purpose of this study to evaluate the imaging potential of different contrast agents.

Three contrast agents for magnetic resonance imaging are compared in angiographies of the supra-aortic arteries in a intraindividual study of 10 patients.

All applications of these contrast agents are performed with a flow of 2 ml/s. One contrast medium is applicated a second time with a reduced flow of 1 ml/s.

The angiographies of the supra-aortic vessels are evaluated by two experienced readers in a consensus reading. The signal/noise- and contrast/noise-ratio of anatomic vessel segments of the carotic and vertebral arteries are measured and compared to each other.

Condition Intervention Phase
Drug: Contrast agent
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Diagnostic
Official Title: Effects on the Diagnostic Accuracy of Magnetic Imaging Angiographies of the Supra-Aortic Vessels by Three Different Magnetic Resonance Contrast Agents in Patients With Headache and Dizziness or Epilepsy and Clinical Indication for an Angiography by Magnetic Imaging

Resource links provided by NLM:

Further study details as provided by University Hospital Muenster:

Primary Outcome Measures:
  • intensity of vessels, muscle, air

Secondary Outcome Measures:
  • signal/noise ratio
  • contrast/nose ratio

Estimated Enrollment: 10
Study Start Date: April 2005
Estimated Study Completion Date: December 2005

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Headache
  • Epilepsia
  • Dizziness

Exclusion Criteria:

  • Pregnancy
  • Metal implants (e.g. pacemaker)
  • Contraindication for contrast agent
  • Multiple allergies
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00132223

Contact: Boris Buerke, MD 00492518345123
Contact: Bernd Tombach, MD 00492518345123

University of Muenster, Dept. of Clinical Radiology Recruiting
Muenster, Germany, 48129
Contact: Boris Buerke, MD    00492518345123   
Contact: Bernd Tombach    00492518345123   
Principal Investigator: Bernd Tombach, MD         
Sub-Investigator: Boris Buerke, MD         
Sponsors and Collaborators
University Hospital Muenster
Study Chair: Bernd Tombach, MD University of Muenster, Dept. of Clinical Radiology
  More Information

No publications provided Identifier: NCT00132223     History of Changes
Other Study ID Numbers: 0710/2004-IKR
Study First Received: August 18, 2005
Last Updated: April 11, 2006
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by University Hospital Muenster:
magnetic imaging
contrast agent
signal/noise ratio
contrast/noise ratio

Additional relevant MeSH terms:
Brain Diseases
Central Nervous System Diseases
Ear Diseases
Labyrinth Diseases
Nervous System Diseases
Neurologic Manifestations
Otorhinolaryngologic Diseases
Sensation Disorders
Signs and Symptoms
Vestibular Diseases
Contrast Media
Diagnostic Uses of Chemicals
Pharmacologic Actions processed this record on October 08, 2015